Patents by Inventor Ruijiang Song

Ruijiang Song has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycan-modified anti-CD4 antibodies for HIV prevention and therapy
    Patent number: 9790276
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 17, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
    Patent number: 9587022
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 7, 2017
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY
    Publication number: 20160362493
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 15, 2016
    Inventors: Ruijiang Song, David D. Ho
  • GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY
    Publication number: 20150166662
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 18, 2015
    Inventors: Ruijiang Song, David D. Ho
  • GLYCAN-MODIFIED ANTI-CD4 ANTIBODIES FOR HIV PREVENTION AND THERAPY
    Publication number: 20140248295
    Abstract: Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.
    Type: Application
    Filed: December 18, 2013
    Publication date: September 4, 2014
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: Ruijiang Song, David D. Ho
  • Fusion antibodies for HIV therapy
    Patent number: 8637024
    Abstract: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 28, 2014
    Assignee: The Rockefeller University
    Inventors: David Ho, Yaoxing Huang, Craig Pace, Ruijiang Song, Qing Fang
  • FUSION PROTEINS FOR HIV THERAPY
    Publication number: 20120121597
    Abstract: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: David Ho, Yaoxing Huang, Craig Pace, Ruijiang Song, Qing Fang